Chicago Equity Partners LLC acquired a new stake in shares of Horizon Pharma PLC (NASDAQ:HZNP) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 136,120 shares of the biopharmaceutical company’s stock, valued at approximately $1,726,000. Chicago Equity Partners LLC owned approximately 0.08% of Horizon Pharma PLC at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in HZNP. BlackRock Inc. grew its stake in shares of Horizon Pharma PLC by 1.8% in the 2nd quarter. BlackRock Inc. now owns 13,500,226 shares of the biopharmaceutical company’s stock valued at $160,247,000 after buying an additional 239,014 shares during the period. Vanguard Group Inc. grew its stake in shares of Horizon Pharma PLC by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 12,982,718 shares of the biopharmaceutical company’s stock valued at $154,105,000 after buying an additional 233,443 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Horizon Pharma PLC by 119.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock valued at $74,373,000 after buying an additional 3,409,411 shares during the period. Paulson & CO. Inc. purchased a new stake in shares of Horizon Pharma PLC in the 2nd quarter valued at approximately $58,584,000. Finally, State Street Corp grew its stake in shares of Horizon Pharma PLC by 12.0% in the 2nd quarter. State Street Corp now owns 4,906,307 shares of the biopharmaceutical company’s stock valued at $58,241,000 after buying an additional 524,187 shares during the period. 83.80% of the stock is owned by institutional investors.
Several analysts have recently weighed in on HZNP shares. ValuEngine cut shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Cantor Fitzgerald set a $13.00 price objective on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Monday, July 31st. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price objective on shares of Horizon Pharma PLC in a report on Sunday, October 22nd. Piper Jaffray Companies set a $18.00 price objective on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Sunday, September 10th. Finally, Zacks Investment Research lowered shares of Horizon Pharma PLC from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $18.42.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) opened at $13.42 on Tuesday. The stock has a market cap of $2,223.93, a P/E ratio of 9.83, a price-to-earnings-growth ratio of 1.15 and a beta of 1.32. Horizon Pharma PLC has a fifty-two week low of $9.45 and a fifty-two week high of $21.98. The company has a current ratio of 1.64, a quick ratio of 1.52 and a debt-to-equity ratio of 1.89.
Horizon Pharma PLC (NASDAQ:HZNP) last released its earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.04. The company had revenue of $271.60 million for the quarter, compared to analyst estimates of $259.74 million. Horizon Pharma PLC had a negative net margin of 45.28% and a positive return on equity of 20.22%. The firm’s quarterly revenue was up 30.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.70 EPS. equities analysts predict that Horizon Pharma PLC will post 0.72 earnings per share for the current year.
Horizon Pharma PLC Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.